IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Stock data | 2024 | Change |
---|---|---|
Price | $0.647 | N/A |
Market Cap | $29.53M | N/A |
Shares Outstanding | 45.64M | N/A |
Employees | 65.00 | N/A |